MedTrace Logo

Pharmacogenetics of Leflunomide in the Management of Rheumatoid Arthritis

NCT07388407 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 110

Last updated 2026-02-05

No results posted yet for this study

Summary

1. Patients taking leflunomide as the only disease-modifying anti-rheumatic drug (DMARD) will be recruited after consent.
2. Blood sample for DNA extraction will be taken The patient will be followed up till two visits 3 months apart, and efficacy and toxicity will be checked using DAS28, ultrasonography, and blood tests for ESR, CRP, anti-CCP, liver function tests, etc. The data form for toxicity will be filled.
3. DNA will be extracted in the laboratory, and SNP will be identified.
4. The efficacy and toxicity data will be studied against the SNPs found
5. An algorithm will be constructed for Pakistani RA patients taking leflunomide.

Conditions

  • Rhematoid Arthritis

Interventions

DRUG

Study for the correlation of SNPs with efficacy and toxicity of Leflunomide in RA patients

Study for the correlation of SNPs with efficacy and toxicity of Leflunomide in RA patients

Sponsors & Collaborators

  • Shifa Tameer-e-Millat University

    collaborator OTHER

  • Foundation University Islamabad

    lead OTHER

Principal Investigators

  • Prof Muzammil Hassan Najmi · Foundation University Islamabad

Eligibility

Min Age
20 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-01
Primary Completion
2026-06-30
Completion
2026-09-30
FDA Drug
Yes

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07388407 on ClinicalTrials.gov